About

Drug development has a gambling problem

Developing a single new drug costs $2.6 billion and takes 12.5 years. Almost all of the drugs that do make it to clinical trials fail, even after rigorous animal testing. The odds of clinical trial success are the equivalent of betting on a single number in roulette, with a 97.3% chance of losing. But despite this colossal failure rate, pharma hasn’t changed its process for creating and testing drugs in 90 years. Pharma keeps placing the same bad bet on animal models, and patients are left to pay the price.

We founded Parallel Bio to solve the real reason why drugs fail.
Our first achievement was the development of the world’s first scalable human immune organoid, designed to capture the human biology that animal models miss. Since then, we’ve reimagined the entire drug discovery process, incorporating cutting edge biological and computational tools to generate unprecedented insights into human health and disease. Our approach allows us to predict how therapies may perform across diverse patient populations, enabling earlier and more reliable decisions than any existing preclinical model. 

Our biobank features donors spanning different ages, sexes, ethnicities, disease states, and genetic backgrounds. With more population diversity than many clinical trials achieve, we generate meaningful data without putting a single patient at risk. When we collect data, we're not asking, "Does this drug work in genetically identical male mice?" We're asking, "How does this drug perform across the actual human population?"
By shifting drug development from guesswork to human-first prediction, we aim to dramatically reduce clinical failures and bring safer, more effective therapies to patients in need. Our new model of pharma will generate medicines for patients 10x faster at a thousandth of the cost, unlock the potential for personalized medicine in ways not previously possible, and generate compounding data rich for modeling and learning in this new era of computational intelligence.
Join us as we push the boundaries of what's possible.
Robert & Juliana

Co-Founders of Parallel Bio

Meet the team

See open roles

Leadership

Experts in organoids, immunology, and AI

Juliana Hilliard

Juliana Hilliard

Co-Founder and Chief Science Officer

Previously
Trained in the lab that invented the first organoid · Commercialized organoids into a fully automated platform at System1 Biosciences, generating multimodal datasets for ML-driven target discovery that Genentech acquired
Education
TU Dresden and Virginia Tech · Bioengineering (MSc)
Robert DiFazio, PhD

Robert DiFazio, PhD

Co-Founder and CEO

Previously
Directed strategy for Stanford’s Institute for Immunity, Transplantation and Infection: 150+ faculty studying human immunology, a $100M+ research portfolio
Education
Immunology, University of Pittsburgh (PhD) · Systems Immunology, Stanford (postdoc) · Chemistry, University of Illinois Urbana-Champaign (BS with High Distinction)
Jason Lew

Jason Lew

Chief AI Officer

Previously
Head of Engineering at a stealth AI startup (evals, agent harnesses, model training) · Co-founder & CTO, MightySignal, acquired by Instacart · Apple
Leads
AI end to end: lab robotics, data infrastructure, models, and partnerships
Education
Electrical & Computer Engineering, Duke (BS) and Cornell (MEng)

How the team fits together

Every experiment makes the models smarter.

And smarter models choose better experiments.

Grow

Human Biology

A biobank of diverse human donors, spanning ages, sexes, ethnicities, disease states, and genetic backgrounds, grown into immune organoids: miniature human immune systems that respond to drugs the way people do.

Learn

AI

A robotic lab that runs experiments at scale, plus scientific reasoning, surrogate models, and ‘world maps’ of health and disease that learn from every run and choose the next experiment.

The team

Fatima Al-Naimi

Fatima Al-Naimi

Research Associate

Lanna Avetisyan

Lanna Avetisyan

Office Manager

Claudio Brun

Claudio Brun

Operations Manager

Belinda Chin

Belinda Chin

Staff Software Engineer

Shona Cronin, PhD

Shona Cronin, PhD

Scientist

Miriana Dardano

Miriana Dardano

Scientist

Ally Gablin

Ally Gablin

Sr. Automation Scientist

Tom Kruitwagen

Tom Kruitwagen

Director, Stem Cell Biology

Teddy Lam

Teddy Lam

IT & Security Lead

Jennifer Lee

Jennifer Lee

VP of Finance and Operations

Yi-Jang Lin, PhD

Yi-Jang Lin, PhD

Senior Scientist

Amanda Merkelson

Amanda Merkelson

Head of Biobanking

Edwin Ramos

Edwin Ramos

Research Associate

Nate Shapiro

Nate Shapiro

Head of Platform

Scientific & AI advisors

Leaders in AI, software engineering, biological data science, immunology and drug development.

AI + Data

Andre Esteva

Andre Esteva

CEO and Co-Founder of ArteraAI, ex-Head of Medical AI at Salesforce

Data Science

Nima Aghaeepour

Nima Aghaeepour

Vice Chair of Research, Professor of Biological Data Science, Stanford

Bioengineering

Darrell Irvine

Darrell Irvine

Professor and Vice-Chair, Department of Immunology & Microbiology, Scripps Research

Immunology

Shane Crotty

Shane Crotty

Professor and CSO, La Jolla Institute for Allergy and Immunology

Pharma

Ron Philip

Ron Philip

Former CEO of Orbital Therapeutics, former CEO of Spark Therapeutics

Government

Rick Bright

Rick Bright

Former Director of BARDA (U.S. HHS), former CEO of the Rockefeller Foundation’s Pandemic Prevention Institute

Backed by

Leading investors from AI and biotech, including Jeff Dean, Marc Benioff, Y Combinator and AIX Ventures.

  • Jeff Dean
  • Marc Benioff
  • Y Combinator
  • AIX Ventures
  • Refactor Capital
  • Metaplanet
  • Atypical Ventures
  • Humba Ventures
  • Amplo
  • Undeterred Capital

Join us

Every experiment brings us closer to a world model of human biology.

We’re hiring across the company: scientists to grow organoids and run experiments, engineers to automate them, and AI researchers to train models on the data.

See open roles